In this regard we will mention the following drugs: SGLT-2 inhibitors, used also in both chronic kidney disease with or without DM, and chronic heart failure, both with or without DM and GLP-1 agonists, used also in the treatment of obesity with or without DM. This evidence concerns the gene SLC5A2 and Obesity.